EVMN
Evommune, Inc.
NYSE: EVMN · HEALTHCARE · BIOTECHNOLOGY
$23.80
-0.21% today
Updated 2026-04-30
Market cap
$914.15M
P/E ratio
—
P/S ratio
70.32x
EPS (TTM)
$-11.22
Dividend yield
—
52W range
$14 – $33
Volume
0.3M
WallStSmart proprietary scores
25
out of 100
Grade: F
Strong Sell
Investment rating
6.0
Growth
B5.0
Quality
C+2.5
Profitability
F5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$51.57
+116.68%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-16.80M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|
| Revenue | $5.00M | $7.00M | $13.00M | $13.00M |
| Net income | $-34.05M | $-66.81M | $-68.87M | $-28.27M |
| EPS | — | — | — | $-11.22 |
| Free cash flow | $-30.09M | $-58.28M | $-76.68M | $-16.80M |
| Profit margin | -681.06% | -954.40% | -529.77% | — |
Peer comparison
Smart narrative
Evommune, Inc. trades at $23.80. Our Smart Value Score of 25/100 indicates the stock is weak. TTM revenue stands at $13.00M.
Frequently asked questions
What is Evommune, Inc.'s stock price?
Evommune, Inc. (EVMN) trades at $23.80.
Is Evommune, Inc. overvalued?
Smart Value Score 25/100 (Grade F, Strong Sell).
What is the price target of Evommune, Inc. (EVMN)?
The analyst target price is $51.57, representing +116.7% upside from the current price of $23.80.
What is Evommune, Inc.'s revenue?
TTM revenue is $13.00M.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio70.32x
ROE-54.40%
Beta—
50D MA$25.65
200D MA$21.89
Shares out0.04B
Float0.02B
Short ratio—
Avg volume0.3M
Performance
1 week-11.91%
1 month+8.59%
3 months+16.59%
YTD+39.54%
1 year—
3 years—
5 years—